Antimicrobial Wound MatrixUltrathin bioresorbable MicroLyte® wound matrix with a polymeric coating containing ionic and metallic silver. It absorbs wound fluid, forms a soft gel, and intimately conforms to the underlying wound-bed to maintain a moist healing environment. The matrix provides a template for cellular growth and is resorbed into the wound bed over 3 days. Silver in the matrix kills 99.99% of bacteria for several days while employing up to 100 times less silver than cover dressings or topical solutions. It reduces the risk of silver toxicity and staining, making it safe for use at the onset of any wound management plan, including burns, donor sites, diabetic ulcers and pressure sores.
Antibiofilm Wound MatrixUltrathin, bioresorbable MicroLyte® wound matrix, that synergistically employ antibiofilm transition metal Gallium and antimicrobial Silver to disrupt biofilms under wound dressings. The matrix prevents formation of bacterial biofilms on a wound-bed and kill bacteria living inside established biofilms. Optimal for application at the onset of wound treatment plan for wounds at risk of infection, and for chronic wounds with signs of biofilms.
Anesthetic Wound MatrixUltrathin bioresorbable wound matrix containing minuscule loadings of local anesthetics to relieve local pain in surgical wounds. The MicroLyte® Matrix technology provides sustained release of anesthetics in the localized microenvironment of a wound-bed, increasing retention time of anesthetic. The matrix can reduce up to 100 times the amount of anesthetics required to relieve local pain (compared to topical or oral formulations), circumventing risks of potential side-effects or addiction in patients with severe or chronic wounds.
Antimicrobial wound matrix market
Wound infection under biologic dressings
Patients with burns and chronic ulcers in US and EU
Growth rate for antimicrobial wound dressings market